Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 18/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335881 | 0.82 | HTT (0.49) | CD38CYP1A2CYP2C19NOS2CYP2D6 | |
| SCHEMBL25201466 | 0.82 | HTT (0.49) | CD38CYP1A2CYP2C19NOS2CYP2D6 | |
| SCHEMBL30261776 | 0.78 | CD38 (0.46) | CD38CYP1A2CYP2C19NOS2CYP2D6 | |
| SCHEMBL25189627 | 0.78 | CD38 (0.46) | CD38CYP1A2CYP2C19NOS2CYP2D6 | |
| SCHEMBL3559627 | 0.78 | CD38 (0.46) | CD38CYP1A2CYP2C19NOS2 | |
| SCHEMBL25485897 | 0.78 | KDM4E (0.45) | CD38CYP1A2CYP2C19NOS2CYP2D6 | |
| SCHEMBL25135797 | 0.77 | CD38 (0.70) | CD38CYP1A2CYP2C19 | |
| SCHEMBL3566113 | 0.77 | CD38 (0.45) | CD38CYP1A2CYP2C19NOS2CYP2D6 | |
| SCHEMBL25490622 | 0.76 | CD38 (0.75) | CD38CYP2C19CYP2D6CYP2B6 | |
| SCHEMBL25135908 | 0.76 | CD38 (0.75) | CD38CYP2C19CYP2D6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | CD38 3165/4885CYP1A2 328/4885CYP2C19 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.